
|Videos|October 15, 2017
Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Author(s)Contagion® Editorial Staff
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
Advertisement
Magda Opsomer, MD, director and clinical leader of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, Belgium, reveals who will benefit from the darunavir single-tablet HIV regimen.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Once-Weekly Oral Islatravir Plus Lenacapavir Maintains HIV Suppression Through 48 Weeks
2
WHO Certifies Countries as Malaria Free in Face of Persistent Antimalarial Drug Resistance
3
Contagion Fall/Winter 2025-2026 Digital Edition
4
WHO Finds Progress in Malaria Prevention Measures
5





























































































































































































































































































